[go: up one dir, main page]

WO2012037349A3 - Compounds - Google Patents

Compounds Download PDF

Info

Publication number
WO2012037349A3
WO2012037349A3 PCT/US2011/051761 US2011051761W WO2012037349A3 WO 2012037349 A3 WO2012037349 A3 WO 2012037349A3 US 2011051761 W US2011051761 W US 2011051761W WO 2012037349 A3 WO2012037349 A3 WO 2012037349A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
trpc3
pharmaceutical compositions
compositions containing
ion channels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/051761
Other languages
French (fr)
Other versions
WO2012037349A2 (en
Inventor
Jason W. Dodson
Joseph Paul Marino Jr.
John Jeffrey Mcatee
Lamont Roscoe Terrell
David G. Washburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of WO2012037349A2 publication Critical patent/WO2012037349A2/en
Anticipated expiration legal-status Critical
Publication of WO2012037349A3 publication Critical patent/WO2012037349A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds, pharmaceutical compositions containing them, and their use treatment of conditions mediated by the TRPC3 and/or TRPC6 ion channels.
PCT/US2011/051761 2010-09-17 2011-09-15 Compounds Ceased WO2012037349A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38388510P 2010-09-17 2010-09-17
US61/383,885 2010-09-17

Publications (2)

Publication Number Publication Date
WO2012037349A2 WO2012037349A2 (en) 2012-03-22
WO2012037349A3 true WO2012037349A3 (en) 2014-03-27

Family

ID=45832238

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/051761 Ceased WO2012037349A2 (en) 2010-09-17 2011-09-15 Compounds

Country Status (1)

Country Link
WO (1) WO2012037349A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014016766A1 (en) 2012-07-25 2014-01-30 Glenmark Pharmaceuticals S.A. Guanidine derivatives as trpc modulators
EP3402330B1 (en) 2016-01-12 2021-12-29 StemoniX Inc. Cell medium formulation for cell stabilization
EP3752499B1 (en) * 2018-02-15 2024-03-27 Boehringer Ingelheim International GmbH Inhibitors of trpc6
AR121846A1 (en) 2020-04-16 2022-07-13 Teijin Pharma Ltd DERIVATIVE OF ARYL OR HETEROARYL
US12059408B2 (en) 2020-08-13 2024-08-13 Boehringer Ingelheim International Gmbh Treatment of cognitive impairment associated with schizophrenia
BR112023004774A2 (en) 2020-10-13 2023-04-25 Boehringer Ingelheim Int REWORK PROCESS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077643A1 (en) * 2000-08-01 2004-04-22 Mikio Ogawa 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient
US20070004711A1 (en) * 2005-05-09 2007-01-04 Suoming Zhang Thiazole compounds and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077643A1 (en) * 2000-08-01 2004-04-22 Mikio Ogawa 3,4 Dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient
US20070004711A1 (en) * 2005-05-09 2007-01-04 Suoming Zhang Thiazole compounds and methods of use

Also Published As

Publication number Publication date
WO2012037349A2 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
IL269858A (en) Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
CA2956871C (en) Compounds active towards bromodomains
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
HK1206028A1 (en) Phenicol antibacterials
EP3315608A4 (en) Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
WO2011103202A3 (en) Androgen receptor modulators and uses thereof
EP3259272A4 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
EP4324527A3 (en) Formulations of enzalutamide
IL233154A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL235767A (en) Substituted pyrrolidines, pharmaceutical compositions comprising the same and uses thereof
WO2012174158A3 (en) Administration of benzodiazepine
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
EP4414376A3 (en) Novel depsipeptide and uses thereof
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
HK1209159A1 (en) Methods of decellularizing bone
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
CL2014000849A1 (en) Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases.
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
WO2011150201A3 (en) Azolyl amide compounds and methods of use thereof
WO2011121576A3 (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
HK1204928A1 (en) Inhibitors of the notch signalling pathway and secretion for use in medicine
WO2015059463A3 (en) Treatment of beta-catenin related diseases8

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11825936

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11825936

Country of ref document: EP

Kind code of ref document: A2